Chronic rhinosinusitis (CRS) is a prevalent disease that is associated with significant costs and quality of life impairments. Currently, patients are classified into subgroups based on clinical characteristics, most often the presence or absence of nasal polyps. However, despite medical and surgical treatment, many of these patients continue to have symptoms. Recent efforts have focused on gaining a more complete understanding of the inflammatory mechanisms that drive pathogenesis in CRS, and it is becoming clear that the inflammatory processes in CRS are quite complex. As our understanding of these complex phenotypes improves, it may become possible to classify patients into endotypes based on unique inflammatory patterns within the sinus mucosa. This information may also lead to the identification of appropriate targeted therapies for different endotypes. This review will discuss our current understanding of endotypes in CRS along with the unique adaptive immune responses that may contribute to these different endotypes and, finally, some potential targeted therapeutics for the next generation of CRS treatment strategies.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s11882-017-0715-0 | DOI Listing |
J Allergy Clin Immunol Pract
January 2025
Department of Otolaryngology-Head and Neck Surgery, University of Iowa, Iowa City, Iowa.
Background: Otitis media with effusion (OME) is associated with comorbidities such as allergic rhinitis, gastroesophageal reflux disease, asthma, and more. Many of these comorbidities can be caused by type 2 inflammation (T2I). This study aims to determine the risk of undergoing OME surgery in patients with and without T2I disease.
View Article and Find Full Text PDFRhinology
December 2024
Department of Head and Neck Surgery and Communication Sciences, Duke University School of Medicine, Durham, NC, USA.
Choosing between revision endoscopic sinus surgery (ESS) versus biologic therapy for recurrent chronic rhinosinusitis with nasal polyposis (CRSwNP) is a complex, multifaceted decision that involves not only clinical and financial factors but also patient preferences. Currently, there are no quantitative studies investigating patient preferences for CRSwNP treatment options. Increased awareness of patient-centered approaches to treatment warrant further investigation.
View Article and Find Full Text PDFJ Allergy Clin Immunol
January 2025
Department of Medicine, Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Jeff and Penny Vinik Center for Translational Immunology Research, Boston, MA, USA 02115.
Ther Clin Risk Manag
January 2025
Department of Otolaryngology Head & Neck Surgery, Monash Health, Melbourne, Australia.
Chronic rhinosinusitis with nasal polyps (CRSwNP) is often severe, debilitating and difficult to treat. Recent randomised control trials (RCTs) of biologics that target key inflammatory pathways have demonstrated clinical efficacy in treating CRSwNP. Such RCTs must facilitate meta-analysis.
View Article and Find Full Text PDFTurk Arch Otorhinolaryngol
January 2025
Yüksekova State Hospital, Department of Otorhinolaryngology and Head & Neck Surgery, Hakkari, Türkiye.
Objective: Inflammatory processes play a role in the etiopathogenesis of chronic rhinosinusitis. Many gene polymorphisms have been associated with inflammation. In this study, we aimed to examine the relationship between angiotensin-converting enzyme insertion/deletion gene polymorphism and chronic rhinosinusitis.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!